The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...

OPUVIZ™, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency ...

OPUVIZ, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen's second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency IN ...

HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – ...

Alteogen announced that it has applied for marketing authorization in Korea for ALT-L9, an aflibercept biosimilar ...

EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...

EU rules that all biosimilars are interchangeable The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have, meanwhile, published a statement confirming that all EU ...

HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES-  SCLC   - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 ...

2 The European Medicines Agency (EMA) approved the trastuzumab biosimilar in 2020 after a series of comparative quality, preclinical, and clinical studies confirmed its similar efficacy and safety to ...

News for EMA India Ltd. Meesho Appoints Hari Bhartia, Kalpana Morparia, Rohit Bhagat as Directors Meesho, the Softbank-backed e-commerce firm, has appointed Jubilant Bhartia Group founder Hari S ...

Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...